康宁杰瑞制药-B(09966)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09966 康宁杰瑞制药-B

开市前 01-09 09:00:37

10.820

+0.000

0.00%

最高10.820	最低10.820	成交量0.00
今开10.820	昨收10.820	日振幅0.00%
总市值104.85亿	流通市值104.85亿	总股本9.69亿
成交额0.00	换手率0.00%	流通股本9.69亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09966","market":"HK","secType":"STK","nameCN":"康宁杰瑞制药-B","latestPrice":10.82,"timestamp":1767920400929,"preClose":10.82,"halted":0,"volume":0,"delay":0,"floatShares":969000000,"shares":969000000,"eps":0.19293291051114225,"marketStatus":"开市前","change":0,"latestTime":"01-09 09:00:37","open":10.82,"high":10.82,"low":10.82,"amount":0,"amplitude":0,"askPrice":11,"askSize":1000,"bidPrice":10.82,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":0.2637097625058438,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767922200000},"marketStatusCode":1,"adr":0,"listingDate":1576080000000,"exchange":"SEHK","adjPreClose":10.82,"openAndCloseTimeList":[[1767922200000,1767931200000],[1767934800000,1767945600000]],"volumeRatio":0,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09966","defaultTab":"news","newsList":[{"id":"2602391591","title":"每日卖空追踪 | 康宁杰瑞制药-B 01月08日卖空量成交5.5万股，卖空比例为1.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602391591","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602391591?lang=zh_cn&edition=full","pubTime":"2026-01-08 16:30","pubTimestamp":1767861044,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B北京时间01月08日，涨6.08%，卖空量成交5.5万股，较上一交易日减少17.91%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108165206a70241cf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108165206a70241cf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09966","BK1161"],"gpt_icon":0},{"id":"2602391328","title":"破局\"冷门\"靶点！科伦博泰ITGB6靶向ADC获批临床，ADC版图再扩张","url":"https://stock-news.laohu8.com/highlight/detail?id=2602391328","media":"制药在线","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602391328?lang=zh_cn&edition=full","pubTime":"2026-01-08 13:29","pubTimestamp":1767850148,"startTime":"0","endTime":"0","summary":"近日，CDE官网显示，科伦博泰1类新药注射用SKB105获得临床试验默示许可，拟用于治疗晚期实体瘤。在SKB105获批临床试验前夕，科伦博泰与美国生物技术公司Crescent围绕该药完成了一笔总额超13亿美元的“双向授权”交易。据Insight数据库，目前全球有10款活跃的ITGB6管线，且主要是ADC。国内药企，如科伦博泰、康宁杰瑞、亲和力生物耶尔积极布局ITGB6靶点。科伦博泰的ADC版图与未来展望SKB105的获批临床，是科伦博泰在ADC领域持续深耕的又一重要里程碑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108132919a70190e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108132919a70190e1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","09966"],"gpt_icon":0},{"id":"2601336363","title":"港股异动 | 康宁杰瑞制药-B(09966)涨超6% 近日SKN033的一项II期临床试验IND申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2601336363","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601336363?lang=zh_cn&edition=full","pubTime":"2026-01-08 10:10","pubTimestamp":1767838222,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康宁杰瑞制药-B涨超6%，截至发稿，涨6.76%，报10.89港元，成交额1041.75万港元。消息面上，近日，康宁杰瑞制药-B发布公告，JSKN033联合铂类化疗联合或不联合贝伐珠单抗一线治疗晚期宫颈癌的一项II期临床试验的新药临床试验申请，已获国家药品监督管理局药品审评中心正式受理。所有患者将接受JSKN033联合顺铂或卡铂联合或不联合贝伐珠单抗的治疗。铂类药物的选择和是否联用贝伐珠单抗将由研究者根据患者的具体情况决定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390200.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","IND","BK1574","09966"],"gpt_icon":0},{"id":"1195331416","title":"康宁杰瑞生物(09966)公布2025年12月股份变动月报：回购736,000股并纳入库存","url":"https://stock-news.laohu8.com/highlight/detail?id=1195331416","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195331416?lang=zh_cn&edition=full","pubTime":"2026-01-06 17:06","pubTimestamp":1767690383,"startTime":"0","endTime":"0","summary":"康宁杰瑞生物制药于2026年1月6日发布2025年12月股份变动月报，报告期为2025年12月1日至12月31日。公司法定注册股本维持25,100,000,000股，面值每股USD 0.000002，注册股本总额USD 50,200，与上月保持一致。本月末公司已发行股份总数保持在974,293,697股。其中，已发行且不含库存股份数量由上月底的969,310,697股降至968,574,697股，库存股份数量相应由4,983,000股增至5,719,000股。该变动主要源于公司于12月1日及12月31日分两次购回合计736,000股股份，并将其持作库存。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"gpt_icon":0},{"id":"2601004332","title":"每日卖空追踪 | 康宁杰瑞制药-B 01月05日卖空量成交7.8万股，卖空比例为4.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601004332","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601004332?lang=zh_cn&edition=full","pubTime":"2026-01-05 16:30","pubTimestamp":1767601842,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B北京时间01月05日，涨1.88%，卖空量成交7.8万股，较上一交易日减少48.34%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105163809a6f52799&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105163809a6f52799&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","09966"],"gpt_icon":0},{"id":"2600450700","title":"智通港股回购统计|1月1日","url":"https://stock-news.laohu8.com/highlight/detail?id=2600450700","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600450700?lang=zh_cn&edition=full","pubTime":"2026-01-01 09:10","pubTimestamp":1767229801,"startTime":"0","endTime":"0","summary":"其中，回购金额最大的为腾讯控股，回购数量106.10 万，回购金额6.35 亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387993.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01274","02886","01868","03650","02869","03798","00700","09966","09922","00345","01588","02598","01810","09886","06608","06098","02018","02038","00314","02416","01995","01516","02866","09857","06100","06831","02621","01897","01024","02391","02517","06609","01600","02121","02509","09959","06078","01672","02586","02678","02299","02652","02419","09878","09896","02219","02142","01651","00909","01458"],"gpt_icon":1},{"id":"2595383727","title":"康宁杰瑞制药-B(09966)12月31日斥资483.35万港元回购50万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2595383727","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595383727?lang=zh_cn&edition=full","pubTime":"2025-12-31 16:59","pubTimestamp":1767171549,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B(09966)发布公告，于2025年12月31日斥资483.35万港元回购50万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387735.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","09966","BK1161"],"gpt_icon":0},{"id":"2595576541","title":"康宁杰瑞制药-B差异化平台助力创新升级，双抗ADC管线未来可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2595576541","media":"西部证券","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595576541?lang=zh_cn&edition=full","pubTime":"2025-12-30 09:14","pubTimestamp":1767057242,"startTime":"0","endTime":"0","summary":"核心结论康宁杰瑞成立于2015年，专注抗肿瘤领域生物创新药开发、生产和商业化。依托单域抗体、双特异性抗体、糖基定点偶联、连接子载荷、双载荷抗体偶联及大分子药物高浓度皮下制剂等核心技术平台，公司开发了兼具差异化优势和国际竞争力的创新管线，涵盖单域抗体、双抗及ADC等抗肿瘤创新药。2025年9月安尼妥单抗HER2+胃癌适应症首个上市申请获NMPA受理，预计2026年内获批，进入商业化放量周期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230100038a6df23cc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230100038a6df23cc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","09966"],"gpt_icon":0},{"id":"2595738276","title":"每日卖空追踪 | 康宁杰瑞制药-B 12月29日卖空量成交3.7万股，卖空比例为2.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595738276","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595738276?lang=zh_cn&edition=full","pubTime":"2025-12-29 16:30","pubTimestamp":1766997041,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B北京时间12月29日，跌2.88%，卖空量成交3.7万股，较上一交易日减少72.99%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229163713a6dc4cbf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229163713a6dc4cbf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","09966"],"gpt_icon":0},{"id":"2595040206","title":"康宁杰瑞制药-B(09966)：JSKN033的一项II期临床试验的IND申请获CDE正式受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2595040206","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595040206?lang=zh_cn&edition=full","pubTime":"2025-12-29 12:17","pubTimestamp":1766981869,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B 发布公告，JSKN033联合铂类化疗联合或不联合贝伐珠单抗一线治疗晚期宫颈癌的一项II期临床试验的新药临床试验申请，已获国家药品监督管理局药品审评中心正式受理。所有患者将接受JSKN033联合顺铂或卡铂联合或不联合贝伐珠单抗的治疗。铂类药物的选择和是否联用贝伐珠单抗将由研究者根据患者的具体情况决定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386406.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","IND","BK4017","LU1223083913.SGD","LU1223082519.USD","BK1574","LU1223082196.USD","09966","CDE"],"gpt_icon":0},{"id":"2593778451","title":"国金证券：首予康宁杰瑞制药-B(09966)“买入”评级 目标价14.30港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2593778451","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593778451?lang=zh_cn&edition=full","pubTime":"2025-12-22 09:56","pubTimestamp":1766368572,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国金证券发布研报称，预测2025/2026/2027年康宁杰瑞制药-B营业收入4.43/4.86/5.50亿元，同比-30.87%/+9.78%/+13.22%，归母净利润-1.05/-0.98/-0.24亿元，同比-162.91%/+6.62%/+75.61%。采用DCF估值法，给予目标价14.30港元/股，首次覆盖，给予“买入”评级。自研HER2双抗KN026在ESMO大会上披露2L+HER2阳性胃癌治疗时展现mPFS和mOs双强阳性疗效，该适应症的上市申请于2025年9月获NMPA受理，预期26H2获批上市，KN026的1L乳腺癌及乳腺癌新辅助预期26H1提交上市申请，预期26/27/28年销售分成为0.05/0.74/1.23亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384224.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09966"],"gpt_icon":0},{"id":"2592663411","title":"每日卖空追踪 | 康宁杰瑞制药-B 12月19日卖空量成交3.8万股，卖空比例为2.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592663411","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592663411?lang=zh_cn&edition=full","pubTime":"2025-12-19 16:30","pubTimestamp":1766133041,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B北京时间12月19日，涨2.25%，卖空量成交3.8万股，较上一交易日减少15.56%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219163722a6b648a7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219163722a6b648a7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","09966"],"gpt_icon":0},{"id":"2592399645","title":"康宁杰瑞制药-B(09966)：JSKN027 IND申请获CDE正式受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2592399645","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592399645?lang=zh_cn&edition=full","pubTime":"2025-12-17 18:08","pubTimestamp":1765966104,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B 发布公告，公司自主研发的程序性死亡配体1/血管内皮生长因子受体2双特异性抗体偶联药物JSKN027新药临床试验申请，已获国家药品监督管理局药品审评中心正式受理。JSKN027是全球首款进入临床研究阶段的PD-L1/VEGFR2双抗ADC药物。临床前数据显示，JSKN027在体外及体内模型中均表现出显著的肿瘤抑制活性。基于其细胞毒杀伤、抗血管生成及免疫调节等多重作用机制，JSKN027有望为多种实体瘤治疗提供新的治疗选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382657.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1223082196.USD","LU1223083913.SGD","CDE","BK1574","BK1161","LU1223082519.USD","IND","09966","BK4017"],"gpt_icon":0},{"id":"2592919097","title":"康宁杰瑞制药-B12月17日遭主力抛售53万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2592919097","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592919097?lang=zh_cn&edition=full","pubTime":"2025-12-17 16:15","pubTimestamp":1765959338,"startTime":"0","endTime":"0","summary":"12月17日, 康宁杰瑞制药-B股价跌0.87%，报收10.23元，成交金额637.4万元，换手率0.07%，振幅2.91%，量比0.52。康宁杰瑞制药-B今日主力资金净流出53万元，上一交易日主力净流出142万元。该股近5个交易日下跌5.13%，主力资金累计净流出105.4万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出1224.6万元，其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217161833a6ad1286&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217161833a6ad1286&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09966","BK1574","BK1161"],"gpt_icon":0},{"id":"2591260344","title":"每日卖空追踪 | 康宁杰瑞制药-B 12月15日卖空量成交1.1万股，卖空比例为0.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591260344","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591260344?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:30","pubTimestamp":1765787441,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B北京时间12月15日，跌1.87%，卖空量成交1.1万股，较上一交易日减少47.62%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215163639a6a45a3b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215163639a6a45a3b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","09966"],"gpt_icon":0},{"id":"2590751580","title":"每日卖空追踪 | 康宁杰瑞制药-B 12月11日卖空量成交2.1万股，卖空比例为1.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590751580","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590751580?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:30","pubTimestamp":1765441840,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B北京时间12月11日，跌1.21%，卖空量成交2.1万股，较上一交易日减少70%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211163754979c69ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211163754979c69ae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09966","BK1574","BK1161"],"gpt_icon":0},{"id":"2590552722","title":"【券商聚焦】交银国际上调康宁杰瑞制药(09966)评级至买入 看好其ADC产品矩阵的巨大全球市场潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2590552722","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590552722?lang=zh_cn&edition=full","pubTime":"2025-12-11 09:06","pubTimestamp":1765415190,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，康宁杰瑞制药 HER2双抗ADC管线加速推进，糖基定点偶联平台持续验证：JSKN003正在进行/即将启动多项注册临床，包括2L HER2+ BC、≥2L HER2低表达BC、PROC和HER2+ CRC。JSKN016单药在TNBC中显示出优异疗效，并正在一项针对晚期NSCLC的Ib期研究中探索与卡铂、伏美替尼、及依沃西单抗等药物的联用方案，预计相关数据将于2026年公布。该机构看好公司ADC产品矩阵的巨大全球市场潜力，上调2025-27年收入预测3-8%、上调DCF目标价至13.0港元、上调评级至买入。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971330","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","09966"],"gpt_icon":0},{"id":"2590931477","title":"每日卖空追踪 | 康宁杰瑞制药-B 12月09日卖空量成交3.2万股，卖空比例为1.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590931477","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590931477?lang=zh_cn&edition=full","pubTime":"2025-12-09 16:30","pubTimestamp":1765269041,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B北京时间12月09日，跌1.74%，卖空量成交3.2万股，较上一交易日减少91.33%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209163643a72cf39f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209163643a72cf39f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09966","BK1161"],"gpt_icon":0},{"id":"2589336980","title":"每日卖空追踪 | 康宁杰瑞制药-B 12月08日卖空量成交18.1万股，卖空比例为9.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589336980","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589336980?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:30","pubTimestamp":1765182640,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B北京时间12月08日，跌6.35%，卖空量成交18.1万股，较上一交易日增加1.69%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025120816364195310ae4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025120816364195310ae4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","09966"],"gpt_icon":0},{"id":"1118634439","title":"康宁杰瑞生物制药（09966）2025年11月股份变动月报：流通股净减764,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1118634439","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118634439?lang=zh_cn&edition=full","pubTime":"2025-12-04 17:12","pubTimestamp":1764839526,"startTime":"0","endTime":"0","summary":"康宁杰瑞生物制药于2025年12月4日发布2025年11月股份变动月报，报告期为2025年11月。公司注册股本维持25,100,000,000股，面值每股USD 0.000002，总额USD 50,200，且无变动。本月末已发行股份为969,310,697股，较上月底减少764,000股；库藏股从上月底的4,073,000股增至4,983,000股，累计增加910,000股。购回方面，公司于2025年11月7日及17日分别以HKD 9.3946及HKD 9.7708的价格购回合计910,000股并将其持作库藏。截止2025年11月30日，公司总股本变为974,293,697股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alphamab.com","stockEarnings":[{"period":"1week","weight":0.1041},{"period":"1month","weight":0.066},{"period":"3month","weight":-0.1715},{"period":"6month","weight":0.5773},{"period":"1year","weight":2.1545},{"period":"ytd","weight":0.1041}],"compareEarnings":[{"period":"1week","weight":0.0202},{"period":"1month","weight":0.0281},{"period":"3month","weight":-0.0054},{"period":"6month","weight":0.0833},{"period":"1year","weight":0.3563},{"period":"ytd","weight":0.0202}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康宁杰瑞生物制药是一家主要从事肿瘤生物制剂研发、制造及商业化的投资控股公司。该公司高度差异化的内部管线由处于不同研发阶段的ADCs、单克隆抗体及双特异性抗体肿瘤药物组成。该公司的候选药物包括KN046（PD-L1/CTLA-4双特异性抗体）, KN026（抗HER2双特异性抗体）, KN035（皮下注射PD-L1）, JSKN003（HER2双表位ADC）等，用于1L sq NSCLC、乳腺癌 2+HER L1、晚期实体瘤、HER2表达实体瘤等适应症。","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.089471},{"month":2,"riseRate":0.666667,"avgChangeRate":0.22886},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.028638},{"month":4,"riseRate":0.833333,"avgChangeRate":0.061128},{"month":5,"riseRate":0.5,"avgChangeRate":-0.016858},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.029877},{"month":7,"riseRate":0.333333,"avgChangeRate":0.059359},{"month":8,"riseRate":0.333333,"avgChangeRate":0.022561},{"month":9,"riseRate":0.333333,"avgChangeRate":0.158319},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.030396},{"month":11,"riseRate":0.5,"avgChangeRate":0.042537},{"month":12,"riseRate":0.5,"avgChangeRate":-0.017716}],"exchange":"SEHK","name":"康宁杰瑞制药-B","nameEN":"ALPHAMAB-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康宁杰瑞制药-B(09966)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康宁杰瑞制药-B(09966)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康宁杰瑞制药-B,09966,康宁杰瑞制药-B股票,康宁杰瑞制药-B股票老虎,康宁杰瑞制药-B股票老虎国际,康宁杰瑞制药-B行情,康宁杰瑞制药-B股票行情,康宁杰瑞制药-B股价,康宁杰瑞制药-B股市,康宁杰瑞制药-B股票价格,康宁杰瑞制药-B股票交易,康宁杰瑞制药-B股票购买,康宁杰瑞制药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康宁杰瑞制药-B(09966)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康宁杰瑞制药-B(09966)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}